Oncology Drug Revenue and Price Negotiation

Aaron P. Mitchell; Rachel E. Sachs; Stacie B. Dusetzina

doi:10.1001/jamaoncol.2025.5385

Oncology Drug Revenue and Price Negotiation

Aaron P. Mitchell
, Rachel E. Sachs
, Stacie B. Dusetzina

Institute of Clinical and Translational Sciences (ICTS)

Research output: Contribution to journal › Comment/debate

Abstract

This Viewpoint examines the potential impacts of the Inflation Reduction Act and negotiation of oncologic drug prices on payments to oncology specialists.

Original language	English
Pages (from-to)	139-140
Number of pages	2
Journal	JAMA oncology
Volume	12
Issue number	2
DOIs	https://doi.org/10.1001/jamaoncol.2025.5385
State	Published - Feb 19 2026

Access to Document

10.1001/jamaoncol.2025.5385

Cite this

@article{aa1f18e7cf2649f78b4985af1e83f83b,

title = "Oncology Drug Revenue and Price Negotiation",

abstract = "This Viewpoint examines the potential impacts of the Inflation Reduction Act and negotiation of oncologic drug prices on payments to oncology specialists.",

author = "Mitchell, \{Aaron P.\} and Sachs, \{Rachel E.\} and Dusetzina, \{Stacie B.\}",

year = "2026",

month = feb,

day = "19",

doi = "10.1001/jamaoncol.2025.5385",

language = "English",

volume = "12",

pages = "139--140",

journal = "JAMA oncology",

issn = "2374-2437",

number = "2",

}

TY - JOUR

T1 - Oncology Drug Revenue and Price Negotiation

AU - Mitchell, Aaron P.

AU - Sachs, Rachel E.

AU - Dusetzina, Stacie B.

PY - 2026/2/19

Y1 - 2026/2/19

N2 - This Viewpoint examines the potential impacts of the Inflation Reduction Act and negotiation of oncologic drug prices on payments to oncology specialists.

AB - This Viewpoint examines the potential impacts of the Inflation Reduction Act and negotiation of oncologic drug prices on payments to oncology specialists.

UR - https://www.scopus.com/pages/publications/105028655182

U2 - 10.1001/jamaoncol.2025.5385

DO - 10.1001/jamaoncol.2025.5385

M3 - Comment/debate

C2 - 41452598

AN - SCOPUS:105028655182

SN - 2374-2437

VL - 12

SP - 139

EP - 140

JO - JAMA oncology

JF - JAMA oncology

IS - 2

ER -

Oncology Drug Revenue and Price Negotiation

Abstract

Access to Document

Other files and links

Fingerprint

Cite this